CONTENTS:
- Lessons learned on addressing racism: Recommendations from The Society for Research on Nicotine and Tobacco's Racial Equity Task Force [Editorial]. Piper M.E., Maddox R., Castro Y., Hinds J.T., Henderson P.N., Clark H., et al., p. 2567-2570.
- The effectiveness of psychosocial interventions at reducing the frequency of alcohol and drug use in parents: findings of a Cochrane Review and meta-analyses. McGovern R., Newham J., Addison M., Hickman M., Kaner E., p. 2571-2582.
- The representation of females in clinical trials for substance use disorder conducted in the United States (2010-19). Gunn C.M., Pankowska M., Harris M., Helsing E., Battaglia T.A., Bagley S.M., p. 2583-2590.
- Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis. Bahji A., Bach P., Danilewitz M., Crockford D., El-Guebaly N., Devoe D.J., et al., p. 2591-2601.
- Prenatal smoking, alcohol and caffeine exposure and offspring externalizing disorders: a systematic review and meta-analysis. Haan E., Westmoreland K.E., Schellhas L., Sallis H.M., Taylor G., Zuccolo L., et al., p. 2602-2613.
- Assessing the impacts of alcohol outlets on crime as a natural experiment: agglomeration, churning and spatial effects. Gruenewald P.J., Sumetsky N., Gaidus A., Ponicki W., Lee J.P., Mair C., p. 2614-2622.
- Commentary on Gruenewald et al.: 'Even one more license may be "too many"'? Morrison C.N., p. 2623-2624.
- Domestication of drinking: a survey study of changes in types of drinking occasions during periods of increasing and decreasing alcohol consumption in the 2000s in Finland. Mäkelä P., Kumpulainen P., Härkönen J., Lintonen T., p. 2625-2634.
- Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs. Adams J.W., Savinkina A., Fox A., Behrends C.N., Madushani R., Wang J., et al., p. 2635-2648.
- Commentary on Adams et al.: Asing administrative big data for the public good. Evans E.A., p. 2649-2650.
- Recreational cannabis legalization and transitions in cannabis use: findings from a nationally representative longitudinal cohort in the United States. Gunadi C., Zhu B., Shi Y., p. 2651-2659.
- Commentary on Gunadi et al.: Opportunities to design more policy-relevant evaluations of non-medical cannabis legalization. Trangenstein P.J., Jernigan D.H., p. 2660-2661.
- Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial. Socias M.E., Wood E., Le Foll B., Lim R., Choi J.C., Mok W.Y., et al., p. 2662-2672.
- Effects of e-cigarette use on mental health among youths: quasi-experimental evidence from Canada. Nguyen H.V., Mital S., p. 2673-2682.
- Characterising the use of varenicline: an analysis of the Australian dispensing claims data. Gobarani R.K., Ilomäki J., Wood S., Abramson M.J., Bonevski B., George J., p. 2683-2694.
- The relationship between smokeless tobacco (snus) and anxiety and depression among adults and elderly people. A comparison to smoking in the Tromso Study. Bondo P., Hoye A., Lochen M.L., Bramness J.G., p. 2695-2706.
- Towards optimum smoking cessation interventions during pregnancy: a household model to explore cost-effectiveness. Saygin Avsar T., Jackson L., Barton P., Jones M., McLeod H., p. 2707-2719.
- Familial associations in adolescent substance use disorder: a population-based cohort study. Hamad A.F., Roos L.L., Bolton J.M., Wall-Wieler E., p. 2720-2729.
- Age-period-cohort analysis of trends in tobacco smoking, cannabis use, and their co-use in the Australian population. Leung J., Gravely S., Lim C., Hall W., Chan G., p. 2730-2735.
- Causal inference with observational data in addiction research. Chan G.C.K., Lim C., Sun T., Stjepanovic D., Connor J., Hall W., et al., p. 2736-2744.
- Rapid changes in illegally manufactured fentanyl products and prices in the United States. Kilmer B., Pardo B., Pujol T.A., Caulkins J.P., p. 2745-2749.
- Naloxone administration - No balance without titration. Skulberg A.K., Tylleskär I., Dale O., p. 2750-2751.
- Prenatal areca nut consumption: overlooked aspects of a widely embraced habit. Balasubramanian S.K., Divya V., p. 2751-2752.
- Challenges and opportunities for further research involving the cannabis-to-opioid use transition. Bahji A., Milloy M.J., Bach P., Socias M.E., p. 2752-2754.
- Response to Bahji et al.: Limitations of the available evidence that restrict our interpretation of the transition from cannabis to opioid use. Wilson J., Mills K.L., Freeman T.P., Sunderland M., Visontay R., Marel C., p. 2754-2755.